Excellent
Fully Aligned
Patient Risk:
Low
Summary
The claim accurately reflects FDA labeling: UBRELVY is indicated for acute treatment of migraine in adults and explicitly is not indicated for preventive treatment.
Category Scores
Accurate Statements
UBRELVY is approved for acute treatment of migraine but not for preventive treatment.
Section 1 — INDICATIONS AND USAGE (UBRELVY indicated for acute treatment in adults; limitation: not indicated for preventive treatment of migraine).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluation is limited to on-label indication (acute vs prevention) and does not include dosing, safety, or risk-mitigation instructions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement